Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) Profit After Tax (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Profit After Tax for 16 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax fell 88.53% year-over-year to $1.7 million, compared with a TTM value of -$27.1 million through Dec 2025, up 51.68%, and an annual FY2025 reading of -$27.1 million, up 51.68% over the prior year.
  • Profit After Tax was $1.7 million for Q4 2025 at Amicus Therapeutics, down from $17.3 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $17.3 million in Q3 2025 and bottomed at -$85.3 million in Q1 2022.
  • Average Profit After Tax over 5 years is -$36.1 million, with a median of -$38.5 million recorded in 2023.
  • Peak annual rise in Profit After Tax hit 357.19% in 2025, while the deepest fall reached 88.53% in 2025.
  • Year by year, Profit After Tax stood at -$83.3 million in 2021, then skyrocketed by 32.92% to -$55.9 million in 2022, then soared by 39.42% to -$33.8 million in 2023, then soared by 143.55% to $14.7 million in 2024, then crashed by 88.53% to $1.7 million in 2025.
  • Business Quant data shows Profit After Tax for FOLD at $1.7 million in Q4 2025, $17.3 million in Q3 2025, and -$24.4 million in Q2 2025.